Stocktoria
Xilio Therapeutics, Inc. XLO
Xilio Therapeutics, Inc. (XLO) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $43.8M at a -80.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.574 |
| Retained earnings / assets | -2.707 |
| EBIT / assets | -0.271 |
| Equity / liabilities | 0.295 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | 4/9 | -6.58 | — | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | 4/9 | -0.86 | — | +17.6% |
| AQST | Aquestive Therapeutics, Inc. | 2/9 | -8.08 | — | -22.6% |
| WVE | Wave Life Sciences Ltd. | 2/9 | 1.15 | — | -60.5% |
| BFRI | Biofrontera Inc. | 1/9 | -15.24 | — | +11.7% |
| SEPN | Septerna, Inc. | 4/9 | 3.75 | — | — |
| PTGX | Protagonist Therapeutics, Inc | 4/9 | 13.41 | — | -89.4% |
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
FAQ
Is XLO financially healthy?
Xilio Therapeutics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does XLO pay a dividend?
No, Xilio Therapeutics, Inc. does not currently pay a dividend.
How profitable is XLO?
In FY2025, Xilio Therapeutics, Inc. had a net margin of -80.1% and a return on equity of -99.3%.
What is the analyst price target for XLO?
The average Wall-Street price target for Xilio Therapeutics, Inc. is $20.00, about 121.0% above the recent price, from 1 analysts.
Is XLO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Xilio Therapeutics, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.